Ionis Pharmaceuticals, Inc. Equity Method Investment, Summarized Financial Information, Revenue (Deprecated 2020-01-31)
Ionis Pharmaceuticals, Inc. (IONS) reported Equity Method Investment, Summarized Financial Information, Revenue (Deprecated 2020-01-31) of $13.79 million for the 12-month period ending 2011-12-31, per its 10-K filed 2012-02-29.
Discontinued › Income Statement › Other Income
us-gaap:EquityMethodInvestmentSummarizedFinancialInformationRevenue · last filed 2012-02-29
- Ionis Pharmaceuticals, Inc. equity method investment, summarized financial information, revenue (deprecated 2020-01-31) for fiscal 2011 was $13.79M, a 60.32% increase from fiscal 2010.
- Ionis Pharmaceuticals, Inc. equity method investment, summarized financial information, revenue (deprecated 2020-01-31) for fiscal 2010 was $8.60M, a 185.46% increase from fiscal 2009.
- Ionis Pharmaceuticals, Inc. equity method investment, summarized financial information, revenue (deprecated 2020-01-31) for fiscal 2009 was $3.01M.
| Period end | Equity Method Investment, Summarized Financial Information, Revenue (Deprecated 2020-01-31) 12 month |
|---|---|
| 2011-12-31 | $13.79M 10-K · filed 2012-02-29 |
| 2010-12-31 | $8.60M 10-K · filed 2012-02-29 |
| 2009-12-31 | $3.01M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |